Tubulis announced that the first antibody-drug conjugate from its strategic partnership with Bristol Myers Squibb has entered clinical development, marking a significant milestone in their 2023 collaboration agreement.
Tubulis has initiated a Phase I/IIa clinical trial (5-STAR 1-01) for TUB-030, a next-generation antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.